
Brentuximab
CAS No. 2088770-90-3
Brentuximab( —— )
Catalog No. M36683 CAS No. 2088770-90-3
Brentuximab, a chimeric antibody targeting CD30, is a naked antibody to Brentuximab vedotin. It possesses antitumor activity and may be used to study relapsed or refractory Hodgkin's lymphoma.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 451 | Get Quote |
![]() ![]() |
5MG | 617 | Get Quote |
![]() ![]() |
10MG | 846 | Get Quote |
![]() ![]() |
25MG | 1242 | Get Quote |
![]() ![]() |
50MG | 1674 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameBrentuximab
-
NoteResearch use only, not for human use.
-
Brief DescriptionBrentuximab, a chimeric antibody targeting CD30, is a naked antibody to Brentuximab vedotin. It possesses antitumor activity and may be used to study relapsed or refractory Hodgkin's lymphoma.
-
DescriptionBrentuximab is a chimeric antibody targeting CD30. Brentuximab can be used for the research of emerging targeted therapies.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetTNF
-
RecptorTNF
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2088770-90-3
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Oh Y, et al. Part II: Prognosis and management. J Am Acad Dermatol. 2021 Nov;85(5):1093-1106.?
molnova catalog



related products
-
Lenalidomide
Lenalidomide (initially known as CC-5013 and marketed as Revlimid? by Celgene) is a derivative of thalidomide introduced in 2004.
-
Menthone
Menthone has anti-inflammary activity it can suppress the lipopolysaccharide (LPS)-induced proinflammatory cytokines interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha)as well as nuclear factor kappaB (NF-kB).
-
α-Humulene
α-Humulene is extracted from S.officinalis essential oil.α-Humulene can inhibit tumor cell growth.α-Humulene also shows anti-inflammatory effects, probably by interfering with TNFalpha production and COX-2 and iNOS expression.